A Study to compare the analgesic effect of Intrathecal 0.5% hyperbaric Bupivacaine with Intrathecal 0.5% hyperbaric Bupivacaine plus Ketamine in patients presenting for Intracavitary High Dose Radiation (HDR) Brachytherapy by Justin Arun Kumar, Arun Kumar
A Study to compare the analgesic effect of Intrathecal 0.5% hyperbaric Bupivacaine with 
Intrathecal 0.5% hyperbaric Bupivacaine plus Ketamine in patients presenting  for 
Intracavitary  High Dose Radiation(HDR)  brachytherapy
By
 
Dr Justin Arun Kumar
A dissertation submitted in partial fulfillment of MD ANAESTHESIOLOGY examination 
conducted by Dr. M. G. R Medical University Tamil Nadu, Chennai to be held in March 2009
                                                      
DEPARTMENT OF ANAESTHESIOLOGY 
CHRISTIAN MEDICAL COLLEGE
VELLORE 632004.
DECLARATION BY THE CANDIDATE
I hereby declare that this dissertation entitled “Study to compare the analgesic effect of Intrathecal  
Hyperbaric Bupivacaine with  Intrathecal Hyperbaric Bupivacaine plus Ketamine in patients  
presenting  for  Intracavitary  High Dose Radiation (HDR)  brachytherapy”  is a bonafide and 
genuine research work carried out by me under the guidance of Dr Sarah Ninan Professor, Head of the 
department of Anaesthesiology, CMC Vellore and Dr Rebecca Jacob  Professor, Department of 
Anaesthesiology, CMC Vellore. 
Date: 
Place: Vellore. Dr Justin Arun Kumar, DA
CERTIFICATE
This is to certify that this dissertation entitled  “Study to compare the analgesic effect of Intrathecal  
Hyperbaric  Bupivacaine  with  Intrathecal  Hyperbaric  Bupivacaine  plus  Ketamine  in  patients  
presenting  for  Intracavitary  High Dose Radiation (HDR)  brachytherapy”  is a bonafide work done 
by  Dr Justin Arun Kumar, under my direct guidance and supervision as a Guide and Head of the 
department  of  Anaesthesiology,  CMC Vellore  in  partial  fulfillment   for  the  requirement   of   MD 
Anaesthesiology examination  conducted  by Dr  M.G.R Medical  University,  Chennai  to  be  held  in 
March 2009.
Date: Dr Sarah Ninan, 
Guide and HOD
Place: Vellore            Department of Anaesthesiology
CMC
Vellore.
Acknowledgments
             I must first thank GOD Almighty in whom I believe, whose presence and blessing was present 
throughout  the  course  of  my  study  and  for  making  the  people  around  me  to  be  so  wonderful, 
cooperative and helpful for the successful completion of this study.
            With a deep sense of gratitude, I would like to acknowledge the guidance rendered to me by 
my  beloved  teacher,  guide  and  mentor  Dr  Rebecca  Jacob  MD  DA  Professor,  Department  of 
Anaesthesiology, CMC, Vellore, who finished her tenure as an Anaesthesiologist in CMC and now 
retired. Her prudent and authoritative retrospection, direction and guidance helped me in completing 
this study.
             I  am grateful to Dr Sarah Ninan MD, DNB Professor and Head of the Department of  
Anaesthesiology, CMC, Vellore for her continuous support, inspiration and guidance. A special note of 
thanks to her for accepting to be my guide in the latter part of this study.
           I wish to express my gratitude to Dr Sujatha Basker MD, DNB Consultant Department of 
Anaesthesiology, CMC, Vellore for her tremendous support and help to complete this study.
         I thank Ms Nithya J, Department of Biostatistics, CMC, Vellore for her help in the statistical 
analysis.
         I also would like to extend my gratitude to my colleagues, friends and the patients for their 
participation in this study. 
  

 CONTENTS                        Page No.
1. INTRODUCTION 02
2. AIM 05
3. OBJECTIVES 06
4. REVIEW OF LITERATURE 07
5. MATERIALS AND METHODS 39
6. RESULTS 46
7. DISCUSSION 62
8. CONCLUSION 67
9. BIBLIOGRAPHY 68
10. APPENDICES
a. INFORMED CONSENT
b. INFORMATION SHEET
c. PROFORMA                                            
d. MASTER CHART
e. GLOSSARY
INTRODUCTION
The choice of treatment for cervical cancer in its early stages is surgery. Radiation or 
chemo-radiation therapies are reserved for high-risk patients in their early stages or in those 
who have advanced disease. Radiation therapy is delivered initially by external beams using 
high  energy  photons  or  gamma  rays  which  is  followed  by  internal  radiation  known  as 
brachytherapy.
 Brachytherapy is given in two forms, one as high dose radiation (HDR) and other as 
low dose radiation (LDR). In both HDR and LDR, applicators are placed in the uterus or 
vagina. Later, radiation is given and the applicators are removed about 4-5 hrs or 24-36 hrs 
after  HDR or LDR respectively.  The period till  the applicators are removed is painful  and 
uncomfortable. Hence relief of pain during this period prevents adverse psychological effects 
in these patients who have already been stressed with a diagnosis of malignancy.
Providing  anaesthesia  to  patients  coming  for  insertion  of  vaginal  applicators  for 
intracavitary high dose brachytherapy involves a higher risk as compared to other patients. 
They could have comorbid factors like advanced age, hypertension, diabetes, ischemic heart 
disease, anaemia etc. and hence are more prone for perioperative complications. The other 
factor is that, they require analgesia and immobilization till the brachytherapy is completed.
This procedure could be performed under general  anaesthesia or under a regional 
technique like a subarachnoid or epidural block. In our set up these patients receive HDR and 
get discharged on the same day and the next fraction is given the following week.  General 
anaesthesia does not provide the required analgesia and immobilization till the applicators are 
removed and could be associated with postoperative nausea and vomiting. As compared to 
general  anaesthesia,  epidural  or  spinal  anaesthesia  is  safe  and  practical.  Epidural 
anaesthesia  through  an  indwelling  catheter  can  provide  adequate  analgesia  and 
immobilization  but  it  is  not  cost  effective  as  these  patients  get  discharged  on  the  same 
evening. 
Subarachnoid  block  is  a  safe,  simple,  rapid  onset  and  cost  effective  regional 
anaesthetic technique as compared to other forms of anaesthesia. Blocking the transmission 
of nociception at the level of the spinal cord has been the main target of study in both acute 
and chronic pain states and various adjuvants are being use to extend the analgesic effect of 
local anaesthetics .  
Spinal  adjuvant  drugs  like  opioids  (fentanyl,  morphine),  ketamine,  clonidine, 
neostigmine,  adrenaline  and  adenosine  are  being  used.  Opioids  can  cause  respiratory 
depression, postoperative nausea and vomiting and urinary retention. Clonidine can cause 
bradycardia, hypotension and sedation while neostigmine can cause nausea and vomiting. 
Adenosine and adrenaline do not prolong the duration of analgesia like the other drugs.
Ketamine is a popular anaesthetic and analgesic and it does not cause any of the side 
effects  mentioned above which is  more important  in  this  group of  patients.  Studies have 
shown that  preservative  free  ketamine as  a spinal  anaesthetic  adjuvant  along with  0.5% 
hyperbaric  bupivacaine  can  provide  adequate  analgesia  and  immobilization  during  the 
insertion of the applicators and till the completion of radiation therapy. 
This prospective double blinded randomized crossover study was designed to assess 
the  duration  of  analgesia  and  to  study  the  effects  of  addition  of  ketamine  to  hyperbaric 
bupivacaine given intrathecally in patients coming for intracavitary brachytherapy.
AIM
“To  study  the  duration  of  analgesia  and  safety  profile  of  intrathecal 
hyperbaric  bupivacaine  with  ketamine  in  patients  coming  for  placement  of 
vaginal applicators for high dose radiation intracavitary brachytherapy”. 
OBJECTIVES
1. Duration of analgesia.
2. Duration of sensory and motor block.
3. Incidence of side effects.
REVIEW OF LITERATURE
The literature has been reviewed under the following headings.
1. Pain and its implications.
2. Spinal anaesthesia.
3. Spinal analgesia.
4. Ketamine 
5. Clinical studies on intrathecal / epidural/ caudal ketamine.
1. Pain and its implications:
International association for the study of pain (IASP)1 defines pain as “an unpleasant 
sensory and emotional experience associated with actual or potential  tissue damage, 
or described in terms of such damage”.
Acute pain in the perioperative setting has been defined as “pain that is present in a 
surgical patient because of preexisting disease, the surgical  procedure (e.g. associated 
drains, chest or nasogastric tubes, complications), or a combination of disease related and 
procedure related sources”. (ASA task force on pain management -acute pain section)2
Acute postoperative pain is a complex reaction to tissue injury, visceral distention or 
disease. It is a manifestation of anatomical and physiological  responses that result in an 
unpleasant sensory and emotional experience.
Pathophysioloqical consequences of pain  3    
1.Cardiovascular  system  -  tachycardia,  hypertension,  increased  systemic  vascular 
resistance and increased cardiac work.
2.Pulmonary system - hypoxia, hypercarbia, atelectasis, decreased cough 
         vital capacity and functional residual capacity, and ventilation perfusion    
         mismatch.
3.Gastrointestinal tract - nausea, vomiting and ileus.
4.Renal - oliguria and urinary retention.
5.Extremities - skeletal muscle pain and restriction of mobility.
6.Endocrine  -  vagal  inhibition,  increased  adrenergic  activity,  metabolism  and    oxygen 
consumption.
7.CNS - anxiety, fear, sedation and fatigue.
8.Immunological - impairment.
Rationale of postoperative pain relief
The aim of postoperative analgesia is to provide subjective comfort and to inhibit 
trauma induced nocioceptive impulses. This is in order to blunt the autonomic and somatic 
reflex responses to pain and subsequently to enhance restoration of function by allowing 
the patients to breathe, cough and ambulate early.
Pain control may have a further benefit of improving clinical outcome by  reducing 
the incidence of postoperative complications such as myocardial  infarction or ischemia, 
impaired wound healing,  atelectasis,  thrombo-embolic  events,  peripheral  vasoconstriction 
and metabolic acidosis.
Effect of post operative analgesia on surgical outcome4
Optimal (dynamic) pain relief is a prerequisite for an early postoperative recovery. A 
reduction  in  the  surgical  stress  response  (endocrine,  metabolic  and  inflammatory)  will 
decrease the incidence of postoperative organ dysfunction and lead to an improved outcome.
Pharmacological Management 5
            During recent years, there has been a tremendous increase in our understanding 
of  the  physiology  of  acute  pain,  development  of  new  analgesics  and  techniques  of 
administration. Various routes which are available for post operative analgesia include 
intramuscular,  subcutaneous,  intravenous,  oral,  rectal,  transdermal,  epidural,  intrathecal, 
caudal etc.
Spinal anaesthesia
History
The first spinal anaesthesia though inadvertently, was produced by Leonard Corning a 
neurologist  in New York (1855 – 1923),  while he was experimenting with cocaine on the 
spinal nerves in dog and accidentally pierced the duramater. His next patient was a man with 
seminal incontinence who developed transient paralysis of the lower limbs after the spinal 
injection. He coined the term ‘Spinal anaesthesia’. Deliberate Lumbar puncture was produced 
by Heinrich Irenaeus Quincke (1842 – 1922) who was aware of the anatomy of the spinal 
cord. 
The first planned spinal anaesthesia for surgery in man was administered by Augustus 
Karl  Gustav Bier (1861-1949) on 16th August 1898, in Kiel.  A surgeon by profession, he 
injected 3 ml of 0.5% cocaine solution into a 34 year old labourer. He also experimented on 
himself with the help of his assistant Hildebrandt. Smith and Porter reported in 1915 that the 
fall in blood pressure after the spinal anaesthetic is due to the paralysis of the vasomotor 
fibres in the splanchnic area and the importance of hyperbaricity. The midline approach was 
demonstrated by Arthur E Barker and the saddle block was demonstrated by Adriani and 
Roman - Vega.6  
Definition
Spinal anaesthesia consists of temporary interruption of the neural transmission within 
the  subarachnoid  space  produced  by  an  injection  of  anaesthetic  solution  into  the 
cerebrospinal fluid.
Anatomy 
Vertebral column consists of 33 vertebrae and 31 pairs of spinal nerves. The spinal 
cord ends at the level of the lower border of L1 vertebra. The structures traversed by the 
needle  while  performing  spinal  anaesthesia  are  skin,  subcutaneous  tissue,  supraspinous 
ligaments, interspinous ligaments, ligamentum flavum, epidural space, duramater, subdural 
space, arachnoid mater and the subarachnoid space where the drug is placed. The piamater 
and spinal cord proper are beneath this space. The contents of the subarachnoid space are 
cerebrospinal fluid, spinal nerves, dentate ligaments (a spongy reticulum of fibres connecting 
the piamater to the arachnoidmater), arteries, veins and lymphatics.
The spinal cord is supplied by three longitudinal arteries, a single anterior spinal artery 
which runs in the anterior commissural fissure which supplies the anterior two thirds of the 
spinal cord. There are two posterior spinal arteries which supply the posterior third of the 
cord. There are radicular arteries which contribute to the anterior and posterior spinal arteries. 
The most important is the anterior radicular artery, called the artery of Adamkiewicz. 
Venous drainage is similar to the arterial blood supply. There are three anterior and 
three posterior veins which drain into the vertebral veins, ascending lumbar veins and the 
azygos veins.
Cerebrospinal fluid (CSF) 
Cerebrospinal fluid was first discovered by Dominico Cotugno in 1764. Its circulation 
was described by F.Magendie in 1825, who christened it as the cerebrospinal fluid7. It is an 
ultra filtrate of plasma with which it is in hydrostatic and osmotic equilibrium. It is secreted 
from the choroids plexus at the rate of 0.3 – 0.4 ml / minute. The total volume is about 120 - 
150 ml of which 25 – 35 ml is in the spinal subarachnoid space. In the horizontal position the 
CSF pressure ranges from 60 – 80 mmH20.
Physical properties  
pH: 7.4
Specific gravity: 1.0069
Proteins: 20mg%
Glucose: 45 – 80 mg%
Density: 1.0003
Baricity:  1.000
Functions:
• It serves to support and cushion the brain against trauma.
• It  removes  waste  products  of  metabolism,  drugs  and  other  substances  that 
diffuse into the brain from the blood.
• It  has  an  important  role  in  integrating  the  brain  and  peripheral  endocrine 
functions.
• The changes in the ionic concentration of calcium, potassium and magnesium in 
the  CSF  may  affect  the  blood  pressure,  heart  rate,  vasomotor  reflexes, 
respiration, muscle tone and emotional state.
spinal column
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Spinal analgesia
        The pharmacology of pain perceived in the spinal cord is complex and almost all the 
receptors found in the CNS are also found in the spinal cord (10). At the periphery most of the 
thermal and mechanical nociceptive signals arise from the activation of polymodal nociceptors 
which are innervated by Aα and C fibres. The mediators are cytokines, nerve growth factors, 
catecholamines, bradyknin, 5-hydroxy tryptamine and prostanoids. 
There  is  considerable  evidence  for  the  involvement  of  excitatory  amino  acids 
glutamate, aspartate and a number of peptides in the nociceptive transmission of pain. They 
include  the  tachykinin  family  of  peptides,  calcitonin  gene  related  peptide  (CGRP), 
somatostatin, vasoactive intestinal peptide, galanin, bombesin and neurotensin. 
The dorsal horn of the spinal cord is the site of termination of the primary afferent 
nociceptive neurons. They end primarily on laminae I,  II,  and V, where they interact with 
various second order neurons. There are two different classes of secondary neurons, the first 
class is known as the “nociceptive specific” or “high threshold” neurons and the second class 
is known as the “wide dynamic range” (WDR) or “convergent” neurons. Nociceptive specific 
neurons are responsive to noxious stimuli and are placed superficially in the dorsal horn. But 
the WDR do not respond to non-noxious stimuli; however they become sensitized and hyper 
responsive by a phenomenon called the “Wind Up”, where even a tactile stimulus will result in 
hyperalgesia.(6)  
These excitatory amino acids act on the NMDA and the non-NMDA receptors and the 
latter  group consists of  alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), 
metabotroipic and kainite. Antagonists against these receptors have gained importance in the 
research on analgesia. There are other receptors involved in the nociceptive transmission or 
modulation and they include the opioid (μ, δ and К), the α-adrenergic, the gamma-amino-
butyric acid (GABA), the serotonin (5HT) and the adenosine receptors.
Modulation of pain
Transmission of pain from periphery is subjected to modulation at various levels of the 
neuraxis.  They  are  inhibited  by  the  local  interneurons  or  the  descending  pathways. 
Modulation at the dorsal horn is by both exogenous and endogenous agents which act on the 
opioid (μ, δ and К), the α-adrenergic, the gamma-amino-butyric acid (GABA), and the glycine 
receptors.
Receptors:
• Opioid receptors
• N-methyl d-aspartate (NMDA)  receptors
• Serotoninergic  receptors
• α-2 adrenergic receptors 
• Cholecystokinin (CCK)  receptors
•  Gamma amino butyric acid (GABA) receptors.
1) Opioid receptors :  
          Opioid receptors form a major spinal inhibitory system in the pain pathway. 
Opioids act by activating three opioid receptors; the mu(μ), delta(δ), and kappa(К). The 
highest  level  of  opioid  receptors  in  the  spinal  cord  are  found  around  the  C-fiber 
terminal  zones  in  lamina  1  and  the  lamina  2  (substantia  gelatinosa)  with  lower 
concentrations in the deeper layers. Lamina 1 and 5 are known to respond principally 
to noxious stimuli, a partial explanation for the analgesic effects of ketamine may be a 
lamina  specific  suppression  of  neuronal  activity.  The  endogenous  opioid  peptides 
namely the enkephalins, dynorphins and endorphins are the natural ligands for these 
receptors which are not entirely specific but a number of other synthetic agents with 
high selectivity are available for study of these receptors. Opioid peptides synthesis 
can be altered in animal models in different pain states. For example, dynorphin levels 
in the spinal cord during inflammation are increased enormously due to the switching 
of the gene for the synthesis of the parent peptide. The peptidase inhibitors can protect 
the breakdown of these peptides and can be used to function as opioids and their 
receptors.
2) N-methyl d-aspartate (NMDA) receptors:  
NMDA receptors belong to the glutamate group of receptors. It is present on the post 
synaptic  neurons  in  the  dorsal  horn.  It  is  activated  by  the  excitatory  amino  acids  like 
glutamate  released  from  the  primary  neurons  in  response  to  noxious  stimulus.  NMDA 
receptors are implicated in many ways in  the spinal  mechanism of  pain  and more so in 
chronic pain states. It is involved in central hyperalgesia and wind up phenomenon. A recent 
clinical study done on disordered central processing in sympathetic dystrophy drive showed 
that local anaesthetics abolished all  symptoms. This system requires a peripheral afferent 
input in the spinal cord which is then amplified and prolonged by a central process with the 
NMDA receptor playing a key role. NMDA receptors are also blocked by high concentrations 
of opioids39. Ketamine is a NMDA receptor antagonist.
3) Serotoninergic receptors:
          There are a significant number of serotoninergic receptors in the spinal cord and 
administration of  serotonin  on the spinal  cord inhibits  the nociceptive neuronal  output. 
Ketamine prevents neuronal uptake of monoamines – serotonin and nor adrenaline and 
increases their concentration at the spinal and the supraspinal levels. The increased levels 
of these monoamines may be responsible for the spinally mediated action of ketamine. 
Antagonists of these monoamines, namely methysergide and phentolamine have been 
proved to antagonize the analgesic effect of ketamine.
 4) α-2 adrenergic receptors:
The descending noradrenergic system from the brain and the midbrain also control 
nociception and can be manipulated by the opioids.
Descending pathways  
This  concept  was  developed  by Melzack  and  Wall  with  the  proposal  of  “the  gate 
theory”. These pathways arise from many supraspinal structures including the hypothalamus, 
periaqueductal  grey  matter  and  nucleus  raphe  magnus.  They  involve  the  action  of 
endogenous opioids, serotonin and GABA. Elucidation of inhibitory pathways is one of the 
modalities  of  pain  control  e.g.  TENS,  deep  brain  stimulation,  epidural  and  spinal  cord 
stimulation.
Ascending pathways:
Spinal  structures involve  the  spinothalamic,  the  spinoreticular,  and  the 
spinomesencephalic tracts  which ascend in the contralateral  side of  the cord.  Acute pain 
could be treated by cordotomy, extralemniscal myelotomy and commissural myelotomy.
          Supraspinal structures The station for the second order neurons is the thalamus. 
Two nuclei  are involved i)  ventro-posterior and ii)  medial  nuclei  and these serve different 
functions. 
         Cortical structures involve two areas i) serving as sensory discriminative component in 
the somatosensory cortex and ii) affecting pain perception in the cingulated cortex.
Ketamine
             Ketamine an anaesthetic and analgesic drug, being a phencyclidine derivative is used 
extensively. 
History: 
In  1958,  phencyclidines  (phenyl  cyclohexyl  piperidine)  were  introduced  in  clinical 
anaesthesia but due to its unacceptable effects like hallucinations, confusion and delirium the 
usage was stopped.  In 1959,  cyclohexamine was tried which had more side effects than 
phencyclidines and had no analgesic effect. 
In 1962 ketamine was synthesized by Stevens and is one of the 200 phencyclidine 
derivatives. It was tried on humans in 1965 and was officially released for clinical use in 1970. 
In 1999 it became a schedule III substance under CSA. 
Chemistry:
Ketamine  is  chemically  a  2-(o-chlorophenyl)--(methylamino) 
cyclohexane (hydrochloride) compound. Ketamine has a chiral center 
and presently marketed as a racemic mixture of its two enantiomers 
S (+) ketamine and R (-) ketamine in NaCl solution with a pH of 3.5 to 
5.5. It is prepared in three concentrations of 10, 50 and 100 mg/ml 
with  benzethonium  chloride  as  a  preservative.   Ketamine  has  a 
molecular weight of 238, is partially water soluble at a pH of 7.4 (pKa –7.5) and 5 - 10 times 
more lipid soluble than thiopental.
Pharmacokinetics:
Its pharmacokinetics can be explained by a two compartment model. Its t½ distribution 
phase is 11 -16 minutes and being very lipid soluble its Vd is 3L/kg. The clearance of the drug 
is  12 -17 ml/kg/min and t  ½ elimination is  2  -3  hours.  The plasma level  of  ketamine for 
hypnosis and amnesia during surgery is approximately 0.7 to 2.2 mcg/ml and awakening 
occurs at a level below 0.5mcg/ml. 
Metabolism:
         Ketamine is metabolized extensively by the hepatic microsomal enzymes, the main 
pathway being demethylation of ketamine by cytochrome P-450 enzyme to norketamine. This 
gets  hydroxylated  and  conjugated  to  form  inactive  water  soluble  glucoronide  metabolites 
which are excreted by the kidneys. Less than 4% of the drug gets excreted unchanged in 
urine and less than 5%  in faeces. 
Isomers :
There are two optical isomers of ketamine due to the presence of an asymmetrical 
carbon atom. These are the positive (S) isomer and the negative (R) isomer. S-isomer as 
compared to R-isomer causes i) intense analgesia ii) rapid metabolism and recovery and iii) a 
lower incidence of emergence reactions. This suggests that they have different sites of action 
and receptors11. 
Pharmacodynamics: 
Central nervous system:
It causes dissociative anaesthesia which is a cataleptic state with   profound analgesia, 
open  eyes  and  intact  corneal,  cough  and  swallow  reflexes  due  to  thalamo-cortical 
dissociation.  Amnesia is  also present  but  may not  be as profound as that  seen with  the 
benzodiazepines. The onset of action is less than 30 seconds. There is pupillary dilatation, 
nystagmus,  lacrimation,  salivation,  an  increase  in  the  muscle  tone  and  purposeless  but 
coordinated  movements  of  the  limbs.  There  is  a  good  correlation  between  the  blood 
concentration and CNS effects which is about 0.6–2 mcg/ml for adults and 0.8–4mcg/ml in 
children and awakening occurs in 15- 30 minutes.
 With the S-enantiomer a slightly lower dose is adequate and due to a 10% increase in 
hepatic  biotransformation  as  compared  to  the  R-  enantiomer  a  faster  recovery  is  seen. 
Analgesia occurs at a plasma concentration of approximately 0.1mcg/ml. Its main action is 
cerebral functional disorganization causing thalamocortical dissociation and an increase in the 
function of the limbic system.
Though controversial it is shown that it can be used in neurologically impaired patients 
as it is does not increase the intracranial pressure and does not cause seizure activity but it 
increases cerebral metabolism and Cmro2. 
Cardio vascular system:
              Ketamine is a known sympathomimetic and it increases the blood pressure and heart 
rate. It acts on the postsynaptic NMDA receptors and the presynaptic afferent processes in 
the medial nucleus tractus solitarius. The C-type afferents which mediate powerful arterial 
baroreflexes effects are also affected12.  Ketamine is also known to have an effect  on the 
parasympathetic cardiac vagal efferent activity through which it causes an increase in the 
heart rate and produces sinus arrhythmia13.
Respiratory system :
Ketamine  is  a  respiratory  stimulant  and  causes  bronchodilatation  due  to  a  NMDA 
receptor independent action by interfering with Ca++  required for bronchoconstriction due to 
histamine release14.  It rarely causes respiratory arrest but increased salivation and retention 
of airway reflexes like cough, gag, sneeze and swallow not adequate for airway safety are 
seen.
Gastro-intestinal:
Peripherally administered ketamine reduces both VMR and motility reflexes, but not at 
doses used in the anaesthetic mixtures (1.8-2.4 mg kg h-1). Effect on the motility reflexes is 
likely to be due to a non-NMDA receptor action, possibly on the nicotinic receptors15.
Other effects  : 
 It  suppresses  the  neutrophil  production  of  inflammatory  mediators  thereby 
improving the blood flow.
 It reduces the migration of leukocytes through endothelial cells.
 It suppresses the proinflammatory cytokine production in blood.
 It  inhibits  the  activity of  hepatic  microsomal  enzymes,  CYP2D1 and CYP3A by 
10-20%.
Mechanism of action: 
            Ketamine is a NMDA blocker with a complicated mechanism of action. It is used both 
as an anaesthetic and analgesic. It acts on many receptors mainly the NMDA and the others 
are the opioid, the serotonin and the muscarinic receptors. 
Orser and Beverley A. MD, in their study showed that ketamine inhibits the NMDA 
receptor by two distinct  mechanisms (1) it  blocks the open channel  and thereby reduces 
mean  channel  open  time  and  (2)  it  decreases  the  frequency of  channel  opening  by  an 
allosteric mechanism16.
Colin J. L. McCartney et al, in their study showed that the mechanism of ketamine and 
dextromethorphan causing preventive analgesia is through inhibition of central sensitization 
and thereby causing a partial opioid tolerance17.
Kawamata  and  Tomoyuki  M.D  in  their  study  showed  that  ketamine  produced 
antinociceptive  effects  through  the  activation  of  the  monoaminergic  descending  inhibitory 
system,  whereas  in  a  unilateral  peripheral  inflammation  induced  hyperalgesic  state,  the 
monoaminergic  system did  not  contribute  to  the  antihyperalgesic  effect  of  ketamine.  The 
mechanisms of antinociceptive and antihyperalgesic properties of ketamine are different18.
Finck.A.Donald M.D. suggested that ketamine induced analgesia is also mediated by 
the opioid receptors as the analgesic effect of ketamine can be antagonized by naloxone19.
At cellular level ketamine blocks the Na+ and the KDR channels in the superficial dorsal 
horn neurons of the lumbar spinal cord at clinically relevant concentrations after local and 
intrathecal administration. Ketamine reduces the excitability of the neurons which may play an 
important role in the complex mechanism of action during spinal anaesthesia20.
Uses: 
a)  Induction  and  maintenance  of  general  anaesthesia  in  ASA  IV  (or  V)  patients  with 
respiratory or cardiovascular disease (other than CAD), especially reactive airway disease or 
hemodynamic compromise due to hypovolemia or intrinsic myocardial  disease (other than 
CAD).
b) Reactive airway disease, asthma 
c) Rapid-sequence induction in otherwise healthy polytrauma victims            following 
massive hemorrhage 
d) Patients in septic shock 
e) Cardiac tamponade and constrictive percarditis (ketamine maintains heart rate and 
filling pressure) 
f) Congenital heart disease, especially with a propensity for R to L shunt 
g) Malignant hyperthermia susceptible patients with a large anterior mediastinal mass 
when spontaneous ventilation is required during induction and intubation 
h) Cardiac anaesthesia for correction of valvular or ischemic heart disease: ketamine 
and  diazepam or  midazolam (with  sufentanil)  by  a  continuous  infusion  because  it 
causes
• minimal hemodynamic pertubations 
• profound analgesia 
• dependable amnesia 
• uneventful convalescence 
i)  Continuous  infusion  of  ketamine  and  propofol for  total  intravenous  anaesthesia 
(TIVA) causes profound analgesia without abolishing spontaneous ventilation. 
Sedation and Analgesia: 
1) Preoperative sedation/analgesia 
2) Sedation (especially paediatric) for procedures  in remote locations  
• Cardiac catheterization 
• Radiation treatment 
• Radiologic studies 
• Change of dressing (e.g. post burn injury) 
• Dental procedures 
3) During primary  propofol sedation/anaesthesia with spontaneous ventilation,  ketamine 
boluses provide  good  analgesia  (without  respiratory depression) during  injection  of 
local anaesthetics. 
4) As a supplement to regional anaesthesia, prior to or after the block 
5) Postoperative analgesia 
Other uses:
1) Treatment of status asthmaticus. 
2) Inhibition of reflex hypertensive response to urinary bladder distension (rats)38. 
3) Treatment of restless leg syndrome (ketamine 30-40 mg PO BID) 
4) It has been suggested that ketamine may be used as an adjunct for psychotherapy in the 
treatment of heroin addiction. 
Doses and routes of administration:
            Ketamine can be administered by the intravenous, intramuscular, oral, rectal, nasal, 
epidural and intrathecal spaces.
General anaesthesia:
1) Intravenous  Induction   0.5 - 2 mg/kg - the peak effect is in 30-60 seconds 
     Maintenance 0.5 - 1 mg/kg IV prn or 20 - 90 mcg/kg/min iv infusion.
2)  For TIVA - continuous iv infusion of propofol  and ketamine in a ratio of (4:1) (e.g. 
propofol 200 mg + ketamine 50 mg) the dose has to be reduced in elderly patients. 
3) Intramuscular induction 4 - 10 mg/kg – the onset of action is 5 minutes and the peak 
effect is in 20 minutes 
4) Sedation/analgesia 
Route Dose
IV 0.2 - 0.8 mg/kg
IM 2 - 4 mg/kg
IV infusion 5 - 10 mcg/kg/min
5) Paediatrics 
Route Dose (mg/kg)
Oral 6  - 10
Nasal 6  - 10
IM 3  – 10
IV 0.5 – 2
Rectal 10
6) Intrathecal:               0.25 – 0.5 mg / kg
7) Epidural / Caudal:       0.5 mg /kg 
Bioavailability 
Route      % bioavailability 
Nasal 50
Oral 20
IM 90
 Emergence Delirium: Emergence from ketamine anaesthesia in the post operative period 
may  be  associated  with  visual,  auditory,  proprioceptive,  and  confusional  illusions  and 
delirium. Cortical blindness may be present. Patient can also have dreams and hallucinations 
during the first 24hrs which usually disappears within few hours. 
The mechanism is due the depression of inferior colliculus and medial geniculate body. 
The incidence may range from 5% - 30% with an increased frequency seen in patients a) age 
>15 yrs b) females c) when the dose is more than 2mg/kg of ketamine and d) a history of 
personality problems. (White et al 1982)
Preventive  measures  include  use  of  benzodiazepines  with  midazolam  being  more 
effective  than  diazepam.  Thiopentone  and dexmedetomidine can  also  be  used  to  treat 
emergence delirium11. 
 
Relative contraindications:
• Patient with intracranial mass and elevated ICP 
• Open eye injury (or whenever increased intraocular pressure would be harmful) 
• As a sole anaesthetic agent in ischemic heart disease 
• Patients with aneurysm 
• Psychotic disease
Safety of Intrathecal ketamine
Intravenous  ketamine  has  shown  to  have  few  neurotoxicity  effects  which  were 
attributed  to  the  preservative  benzethonium  chloride  or  chlorobutanol. When  given 
intravenously it was shown to cause brain cell death in perinatal rhesus monkey21. There were 
three cases of blindness reported by Fine Joseph et al after the use of ketamine22.
Even preservative free Intrathecal ketamine was found to produce histopathological 
changes suggesting neuronal  injury in  rabbits,  but  this  was seen on repeated intrathecal 
injections and was also dependent on the dose of the drug40. It was shown by Brock et al that 
intrathecal ketamine does not cause any macroscopic change but microscopically has caused 
edema of the nerve roots23. Borgbjerg confirmed the lack of neurotoxicity on light and electron 
microscopy24. 
Ketamine - Dreams and realities25
              Ketamine though used mainly as an anaesthetic, can cause vivid dreams and hence 
it is used as a party drug.  The other street names are Super K, Kitkat, Ecstasy, Green K, 
Purple,  Special  la  coke,  Jet,  Honey oil  and Super  acid.  It  is  illegal  to  possess ketamine 
without a license or a prescription in the USA. In India it is still available as an on the counter 
drug and is slowly becoming popular as a party drug. It is also known to give a “near death 
experience”. Ketamine as a drug of abuse can be mixed in beverages, smoked, and injected 
intramuscularly. 
Clinical studies on Intrathecal / Epidural/ Caudal Ketamine  . 
Yatindra Kumar Batra et al conducted a study to  determine whether ketamine alone or in 
combination with bupivacaine provided superior  pain relief  after  surgery in patients undergoing 
knee arthroscopy. He observed that intraarticular bupivacaine with ketamine provided better pain 
relief than plain in day care arthroscopic knee surgery26.
 Togal T et al studied conducted a study  to evaluate the effects of intrathecal  S (+) 
ketamine  added  to  a  small  dose  of  spinal  bupivacaine  in  elderly  patients  undergoing 
transurethral prostate surgery. He concluded that Intrathecal S(+) ketamine administered with 
a small dose of bupivacaine provided a shorter onset time of motor and sensory block, a 
shorter duration of action and a lesser motor blockade in elderly males27.
Vranken J H et al reported about a patient with severe neuropathic cancer pain who 
was  successfully  treated  by  continuous  intrathecal  infusion  of  morphine,  bupivacaine, 
clonidine and S (+)-ketamine. The quality of life before and three weeks after the onset of 
spinal treatment revealed an improvement in pain relief. No clinical sign of neurologic deficit 
was  observed  during  the  spinal  treatment  with  S  (+)-ketamine.  However,  continuous 
intrathecal  administration of  S  (+)-ketamine should be considered as  the  last  modality of 
analgesia as there is no preclinical safety data on the use of intrathecal S (+)-ketamine28.
Bion et al studied the effect of intrathecal ketamine for surgeries in war casualities. He 
observed that the dose of ketamine to produce clinical anaesthesia was 1-2 mg/kg and the 
duration  of  analgesia  was  40-45  minutes  which  was  devoid  of  respiratory  and  cardiac 
depression. The degree of sedation was more when a higher dose was used29.
 Bhattacharya D studied 100 patients belonging to ASA I and II grades scheduled for 
lower abdomen and lower extremity surgery under spinal anaesthesia who were divided into 
two groups of 50 patients each. The first group received 0.5% hyperbaric bupivacaine while 
the second group received a solution containing 2 ml of  ketamine (100 mg),  2 ml of  5% 
dextrose and 1 ml of 1 in 10,000 adrenaline (0.1 mg). From the study, it was concluded that 
intrathecal  ketamine with 0.5% bupivacaine as compared to  plain 0.5% bupivacaine  had 
significant clinical properties like shorter onset of sensory and motor block, shorter duration of 
sensory block, an almost equal duration of motor block, minimal changes in systolic blood 
pressure  and pulse rate  and a longer duration of postoperative analgesia. The intensity of 
analgesia, gradation of motor paralysis and central effects (sedation) in the ketamine with 
hyperbaric bupivacaine group was more than in the plain hyperbaric bupivacaine group30.
Benrath J et al reported a patient with urethral carcinoma who had chronic neuropathic 
pain  and  was  treated  successfully  with  intrathecal  administration  of  S  (+)-ketamine  and 
morphine. Plasma concentration of S (+)-ketamine was measured regularly throughout the 
treatment  and  continuous  administration  of  S  (+)-ketamine  over  a  period  of  3  months 
demonstrated a low plasma level and no unwanted side effects31.
Bansal et al used intrathecal ketamine in three doses of 50, 75, and 100 mg with and 
without adrenaline for emergency surgeries on lower limbs and lower abdomen. They found 
that the sensory block was adequate in all the cases and observed motor block with higher 
doses of ketamine. There was no respiratory or cardiovascular depression and the duration of 
analgesia lasted for about 1-3 hours32.
Khubchand used ketamine 50mg intrathecally for  a  case of  ruptured uterus  and it 
provided satisfactory analgesia for the surgery without untoward cardiovascular or respiratory 
complications33.  Sekaran  et  al  administered  autoclaved  preservative  free  ketamine 
intrathecally in a known asthmatic and found spinal ketamine as an effective and efficient 
mode of anaesthesia42. 
Yanli Y et al conducted a  randomized, double blinded study on 30 patients  comparing 
two regimens for extradural anaesthesia - 20 ml of 0.5% bupivacaine, 25 mg of ketamine and 
1 in 200 000 adrenaline with 20 ml of 0.5% bupivacaine, 0.5 ml of 0.9% saline and 1 in 200 
000  adrenaline.  The  main  outcome  measures  were  onset  time  for  acceptable  bilateral 
anaesthesia and duration of postoperative analgesia. The time of onset of anaesthesia was 
reduced by 8 minutes in the bupivacaine-ketamine group as compared to the bupivacaine-
saline group. In addition, the anaesthetic level was two segments higher in the bupivacaine-
ketamine group (T7 versus T9)  and side effects  were  similar  in both the groups with  no 
significant difference in the postoperative analgesic requirements between the groups. The 
addition of ketamine to bupivacaine given epidurally appears to be useful to reduce the onset 
time of blockade34.
Punjabi  N  et  al  studied  sixty  paediatric  patients  aged  6  months  to  10  years  who 
underwent  inguinal  herniotomy and  they  were  randomly  allocated  to  receive  1  of  the  3 
solutions for a caudal epidural block. Group 1 received 0.75 ml/kg of 0.25% bupivacaine with 
0.25 mg/kg of preservative-free ketamine, group 2 received 0.75 mL/kg of 0.25% bupivacaine 
with 0.5 mg/kg of ketamine, and group 3 received 0.75 mL/kg of 0.25% bupivacaine with 1 
mg/kg of ketamine. They concluded that the mean duration of caudal analgesia was 8.8 hours 
in group 1 as compared to 22.1 hours in group 2 and 25.2 hours in group 3. Supplemental 
analgesic requirements with pethidine was significantly less in group 2 (4 subjects) and group 
3 (no subject) as compared to group 1 (18 subjects). There was no difference in the incidence 
of motor blockade, urinary retention, emesis or sedation between the groups. Group 3 had a 
significantly higher incidence of side effects such as odd behavior, agitation and restlessness 
than groups 1 and 2. Thus they concluded in their study that the optimal dose of ketamine 
was 0.5 mg/kg added to 0.75 mL/kg of 0.25% bupivacaine for caudal epidural block without 
an increase in the incidence of side effects35.
Kathirvel S et al studied the effect of bupivacaine with and without ketamine in patients 
who underwent  intracavitary brachytherapy.  He found that  the onset  time of  sensory and 
motor block and the duration of spinal analgesia were comparable between the groups. The 
duration  of  motor  blockade  was  shorter  and  requirement  for  intravenous  fluids  in  the 
perioperative period was lesser in  the ketamine group. Significantly,  more patients in  the 
ketamine group had adverse events like sedation, dizziness, nystagmus, strange feelings and 
postoperative nausea and vomiting. It was concluded that although the addition of ketamine 
to spinal bupivacaine had a local anaesthetic additive effect, it did not provide postoperative 
analgesia and the central adverse effects of ketamine limited its spinal use36.
MATERIAL AND METHODS
Study area:  Christian Medical College & Hospital, Vellore, known as "CMC Vellore", was 
founded by Dr. Ida S. Scudder and is located in the city of Vellore in Tamil Nadu, South 
India. It is a 2234 bedded tertiary care medical center.
Study subjects: 
Patients who underwent intracavitary high dose radiation for cancer cervix.
Scientific title of research scheme:  Prospective double blinded randomized cross over study to 
compare the analgesic effect of Intrathecal hyperbaric bupivacaine with Intrathecal hyperbaric 
bupivacaine  plus  ketamine  in  patients  coming  for  intracavitary  high  dose  radiation  (HDR) 
brachytherapy 
Study Type: Prospective double blinded randomized crossover study.
Selection criteria:
Inclusion Criteria:  All cases of cancer cervix.
Exclusion Criteria:  ASA III and IV
                                  Weight <35 Kg.
Method of randomization: Block randomization of 4 subjects each. In this case six possible 
sequences  existed  (1122,  1212,  1221,  2211,  2121  and  2112)  and  these  sequences  or 
“blocks” were randomly selected till the desired sample size was reached. 
Method  of  allocation  concealment: The  anaesthetist  who  performs  the  block  will  be 
informed to which group the patient belongs by the operation theatre staff who is in charge of 
the  randomization  list  and accordingly  the  patient  will  receive  spinal  bupivacaine  with  or 
without ketamine.
Blinding and masking:  Except  the anaesthetist  who does the block,  all  are other  staff 
members are blinded to the drug injected into the subarachnoid space.
Primary outcome: Duration of analgesia of Intrathecal bupivacaine with         ketamine.
Secondary Outcome/s: 1. Duration of sensory and motor block.
          2. Incidence of side effects like nausea and vomiting, illusions, 
dreaming, shivering, pruritis, emergence delirium and nystagmus.
Sample size and rationale: The required sample to compare the analgesic duration between 
the two groups was found to be 20 with a power of 80% with an alpha level significance of 
5%.
(This dissertation is based on the pioneer study titled “Effects of Intrathecal Ketamine 
added to bupivacaine for spinal anaesthesia”   Authors: Kathirvel,S.;  Sadhasivam,S.;  
Saxena,A.  Kannan,T.R.;  Ganjoo,P.   Source: Anaesthesia,  Volume 55, Number  9, 
September 2000, pp. 899-904(6)
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 2/1 α−Z  = 1.96 (5% alpha level of significance)
β−1Z  = 0.842 (80% power)
d = difference between the two means
              n / 2 in each group
Ref:  1)  Design and Analysis of Cross Over Trials by Byron Jones and    Michael  and 
Kenward.
        2) Monographers on Statistics and Applied Probability -98 Chapton and Hall 
publications pg - 34
The above studies give the duration of analgesia as one of the monitoring variable which 
is my primary outcome.  Values are mean of 190.7 and 186.3 and SD   of 26 and 20.1  . 
Using the above formula:                                                                             
            n     =              2 x (1.96 + 0.842)2  x [(26+20.1)/2]2
                                                 (190.7 + 186.3) / 2        
                    =                 2 x 7.851204 x 23.05  
                                   19.36
                     =                 18.69
                n   =                 ~ 20
    Therefore each arm will have 10 patients.     
Date of first enrolment: June 1st 2008
Estimated duration of trial:  3 months
Methodology: 
 Patients who receive HDR get 2 fractions of brachytherapy. They will  be randomly 
divided into groups A or B. Group A will receive 2 ml of 0.5% hyperbaric bupivacaine during 
the 1st fraction and 1.5 ml of 0.5% hyperbaric bupivacaine with 0.5 mg/kg of preservative free 
ketamine during the 2nd fraction. Group B will receive 1.5 ml of 0.5% hyperbaric bupivacaine 
with  0.5  mg/kg  of  preservative  free  ketamine  during  the  1st fraction  and  2  ml  of 
0.5%hyperbaric bupivacaine during the 2nd fraction.  So each patient will  thus be her own 
control.
MODEL
HDR    Patients
Group 1st Fraction 2nd Fraction
A
2ml of 0.5% hyperbaric 
Bupivacaine
1.5 ml of 0.5% 
hyperbaric Bupivacaine
+
0.5 mg/kg of Ketamine
B
1.5 ml of 0.5% 
hyperbaric Bupivacaine
+
0.5 mg/kg of Ketamine
2 ml of 0.5% hyperbaric 
Bupivacaine
Patients from groups A and B who are given a combination of 0.5% hyperbaric bupivacaine 
with  ketamine intrathecally will  belong to the study group and those who are given 0.5% 
hyperbaric bupivacaine intrathecally will belong to the control group. 
Intervention and Comparator agent
                On the previous day the anaesthetist meets the patient, explains about the study 
and gets an informed consent signed. The patient is kept fasting on the day of the procedure 
and a premedication of diazepam and metocloperamide is given. Anaesthesia machine and 
airway equipment are checked according to ASA guidelines. Drugs like atropine, adrenaline, 
ephedrine, thiopentone and succinylcholine are kept ready.
Patient  is  then shifted to  the operation theatre  and monitoring like pulse oximeter, 
noninvasive blood pressure and electrocardiogram are established. An intravenous access 
with 20G cannula is attained under aseptic precautions and a 500ml normal saline or ringer 
lactate solution is connected for preloading during spinal anaesthesia.
A  baseline  recording  of  pulse  rate,  blood  pressure  and  spo2  is  noted.  Then  the 
randomization  chart  is  checked  and  anaesthesia  is  planned  accordingly.  Under  aseptic 
precautions lumbar puncture is performed using an appropriate needle at the L2-L3 / L3-L4 
space. The study drug is injected after confirming the free flow of CSF. 
The time of onset of sensory and motor block is noted. Sensory blockade is assessed 
by loss of  pin prick sensation in T10-T12 region and motor block is assessed by loss of 
mobility of foot. Then the patient is shifted to the lithotomy position for the placement of the 
applicators. During this period vital signs are monitored at 10, 20, 30, 45, 60, 75, 90, 105 and 
120 minutes or till  the patient  is  shifted to the recovery room from the operation theatre. 
Intraoperatively  complications  like  illusions,  dreaming,  shivering,  pruritis,  vomiting  and 
nystagmus are checked and treated accordingly. 
In the recovery room the nurse monitors the patient till the return of sensory and motor 
function after which she is shifted to the radiotherapy suite. During this period the patient is 
monitored by the radiotherapy physicians. The time and the pain score at which the patient 
asks for an analgesic is noted and a rescue analgesic is given. This period is considered as 
the  duration  of  analgesia  provided by spinal  anaesthesia.  The data  is  collected  and  the 
groups are compared statistically.
         
RESULTS
Duration of sensory blockade
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FIGURE - 3
Comparison of duration of sensory blockade 
between the study group and the control group
TABLE - 1
On comparing the duration of sensory block in the study and control groups, the study group 
had  a  mean  (SD)  duration  of  83.55(13.62)  minutes  and  control  group  had  81.09(11.90) 
minutes. On comparing the groups by the paired‘t’  test it was found to have a p value of 
0.526.  Hence  this  study showed that  there  is  no  statistically  significant  difference  in  the 
duration of sensory block between the study and control groups.
Mean Std. Deviation
Study 83.55 13.62
Control 81.09 11.90
Mean SD t Df Significance
2.45455 17.87184 0.644 21 0.526
Duration of motor blockade 
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FIGURE - 4
Comparison of duration of motor blockade between 
the study group and the control group
Mean SD T Df Significance
-0.31818 18.73471 -0.080 21 0.937
TABLE - 2
The duration of motor block was compared between the study and control groups. The study 
group showed a mean (SD) duration of 87.59(14.35) minutes and control group 87.90(15.15) 
minutes. When compared statistically using the paired‘t’ test, it showed a p value of 0.937 
with no significant difference in the duration of motor block.
Duration of analgesia
Mean Std. DeviationStudy 87.59 14.352
Control 87.9091 15.15290
3
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
3.9
4
DU
RA
TI
O
N
 IN
 H
O
UR
S
STUDY CONTROL
FIGURE - 5
Comparison of duration of analgesia between the 
study group and the control group
TABLE - 3
The study and control groups were compared regarding the duration of analgesia. It was seen 
that  the  study  group  had  a  mean  (SD)  duration  of  3.95(0.705)  hours  and  control  had 
4.00(0.88) hours. On comparing these two groups using the paired‘t’ test a p value of 0.797 
was obtained , which shows that there is no significant difference between the two groups 
regarding the duration of analgesia.
The difference in the durations of sensory, motor 
blockade and analgesia between fractions 1and 2 
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Sensory Motor Analgesia
Fraction 1
Fraction 2
Mean Std. Deviation
Study 3.9518 0.70538
Control 4.0091 0.88158
Mean SD T Df Significan
ce
-.05727 1.03100 -0.261 21 0.797
FIGURE - 6
The difference in the durations of sensory, motor 
blockade and analgesia between   fractions 1 and 2  
TABLE - 4
The patients were compared between the first and the second fraction irrespective of the type 
of  treatment  they  had  received  based  on  the  duration  of  sensory  and  motor  block  and 
analgesia. The p values were 0.526, 0.937, and 0.797 for sensory blockade, motor blockade 
Mean SD T Df Significance
Duration of 
sensory 
blockade
2.45455 17.87184 0.644 21 0.526
Duration of 
motor 
blockade
-0.31818 18.73471 -0.080 21 0.937
Duration of 
analgesia -.05727 1.03100 -0.261 21 0.797
and  duration  of  analgesia  respectively.  It  was  found  to  have  no  statistically  significant 
difference  in  the  duration  of  sensory  and  motor  block  and  analgesia  irrespective  of  the 
number of fraction.
Comparison of systolic BP
FIGURE - 7
% Change in systolic BP 
Change in 
systolic BP %
10 minutes
Mean (SD)
60 minutes
Mean (SD)
90minutes
Mean(SD)
Study -3.90 (8.65) -7.00 (8.24) -5.22 (6.65)
Control -5.16 (-5.15) -3.47 (15.89) -3.55 (14.80)
t -0.542 -1.101 -0.492
Deg of freedom 21 20 18
Significance 0.593 0.284 0.629
TABLE - 5
In the study group the fall in systolic BP from the baseline was 3.90%(8.65) at 10 minutes, 7% 
(8.24) at 60 minutes and  5.22%(6.65) at 90 minutes as compared to the control group where 
there was a fall of 5.16%(5.15), 3.47%(15.89) and 3.55%(14.80) at 10, 60 and 90 minutes 
respectively.  By using the paired‘t’ test it was found to have  p values of 0.593, 0.284 and 
0.629 at 10, 60 and 90 minutes, which is not statistically significant. 
% Change in Diastolic BP 
FIGURE - 8
%Change in Diastolic BP 
TABLE - 6
In the study group the fall in diastolic BP from the baseline was 5.95%(10.25) at 10 minutes, 
6.83% (16.55) at 60 minutes and  2.56%(16.09) at 90 minutes as compared to the control 
group where there was a fall of 6.31%(7.177), 8.12%(8.48) and 7.28%(6.75) at 10, 60 and 90 
minutes respectively. By using the paired‘t’ test it was found to have p values of 0.891, 0.751 
and 0.169 at 10, 60 and 90 minutes, which is not statistically significant. 
% Change in heart rate 
Change in 
Diastolic BP %
10 minutes
Mean (SD)
60 minutes
Mean (SD)
90minutes
Mean(SD)
Study -5.95(10.25) -6.83(16.55) -2.56(16.09)
Control -6.31(7.177) -8.12(8.48) -7.28(6.75)
Test statistic 0.139 0.322 1.435
Deg of freedom 21 20 18
Significance 0.891 0.751 0.169
FIGURE - 9
% Change in heart rate
Change in 
Heart rate %
10 minutes
Mean (SD)
60 minutes
Mean (SD)
90minutes
Mean(SD)
Study -1.32(5.46) -6.48 (10.13) -7.55 (9.83)
Control -1.55 (6.65) -4.08 (8.62) -4.92 (7.34)
t -0.119 -0.880 -0.947
Deg of freedom 21 20 17
Significance 0.906 0.389 0.357
TABLE - 7
In  the  study  group  the  fall  in  heart  rate  the  baseline  was  1.32%(5.46)  at  10  minutes, 
6.48%(10.13) at 60 minutes and  7.55%(9.83) at 90 minutes as compared to the control group 
where  there  was  a  fall  of  1.55%(6.65),  4.08% (8.62)  and 4.92%(7.34)  at  10,  60  and 90 
minutes respectively. By using the paired‘t’ test it was found to have  p values of 0.906, 0.389 
and 0.357 at 10, 60 and 90 minutes, which is not statistically significant. 
Comparison of side effects
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FIGURE - 10
Comparison of side effects
Control (%) Study (%)
Vomiting 1 (4.54) 8 (36.36)
Illusions 0 1 (4.54)
Nil 21 (95.45) 14 (63.63)
Total 22 (100) 22 (100)
TABLE - 8
The groups were also compared for the incidence of side effects. The control (bupivacaine 
only) group had only 1 patient out of 22 (4.5%) but the study (bupivacaine + ketamine) group 
had 8 patients who vomited (36.36 %). 1 patient from the study group had illusions (4.54%) 
but none in the control group.
Discussion
            The goal of an anaesthetic is to provide ideal surgical conditions and a pain free state 
extending into the post operative period. Every spinal anaesthetic agent in current practice 
aims to achieve this goal. Some of the spinal adjuvant drugs in use are morphine, fentanyl, 
pethidine,  clonidine,  ketamine  and  neostigmine.  Intrathecal  administration  of  local 
anaesthetics and narcotics in combination has unrivaled effectiveness in spinal anaesthesia. 
However opioids’ side effects like nausea, vomiting, pruritis, urinary retention and respiratory 
depression necessitate intervention and delays discharge. Clonidine causes hypotension and 
sedation while neostigmine causes nausea and vomiting. 
Ketamine, a phencyclidine derivative is a well known anaesthetic and analgesic and 
can also be given intrathecally. It can be used as a sole drug or as an adjuvant with a local 
anaesthetic and this combination can reduce the total dose of both the drugs and thus their 
side effects. The intrathecal dose is lower than the intravenous dose which is well known to 
have various side effects.
Our  study  compared  the  duration  of  analgesia  of  intrathecal  0.5%  hyperbaric 
bupivacaine with intrathecal 0.5% hyperbaric bupivacaine plus ketamine in patients posted for 
intracavitary high dose radiation (HDR) brachytherapy. Group A received bupivacaine during 
the  1st fraction  and  bupivacaine  with  ketamine  during  the  2nd fraction.  Group  B  received 
bupivacaine  with  ketamine  during  the  1st fraction  and  bupivacaine  alone  during  the  2nd 
fraction. Thus each patient was her own control. The dose of 0.5% hyperbaric bupivacaine 
was 2.0 ml when administered alone and 1.5 ml when combined with 0.5 mg/kg of ketamine. 
Since these patients have severe pain when the packs are being removed about 4-5 hours 
later and should be discharged home the same day in a pain free state, oriented and with the 
absence of side effects like vomiting and respiratory depression, this study was done aiming 
to achieve this goal.
Duration of analgesia 
        The primary outcome of our study was to assess the duration of analgesia between the 
two groups. The mean duration of analgesia in the control group was 4.0091(SD 0.88158) hrs 
and in the study group it was 3.9518(SD 0.70538) by using the paired‘t’ test and a p valve of 
0.797. Though there is a reduction in the duration of analgesia in the study group it is not 
statistically significant #28) (#27). 
The study also shows that there is no statistically significant difference in the duration 
of analgesia when ketamine was given in the first or the second fraction. 
Duration of sensory blockade
The mean duration of sensory block in the study group was 83.55(SD13.623) minutes 
and in the control group it was 81.09(SD11.90) minutes. By using the paired‘t’ test a p value 
of 0.526 was obtained which is not statistically significant.  Bhattacharya D et al in his study 
showed that when bupivacaine is combined with ketamine, it produced a shorter duration of 
sensory blockade30.
Duration of motor blockade
Like the duration of sensory blockade, the difference in the duration of motor block 
between the study and control groups was not statistically significant. The mean duration of 
motor block in the study group was 87.59(SD14.35) minutes and in the control group it was 
87.90(SD15.15) minutes with a p value of 0.937.
The effect on blood pressure
Blood pressure was checked at 10, 20, 30, 45, 60, 75, 90, and 105 minutes of the 
procedure. Both the groups did not show statistically significant difference in the fall in BP as 
compared  to  the  baseline  values.  Both  the  groups  had  a  similar  fall  of  systolic  BP  to 
approximately 8-10% and a fall of diastolic BP to approximately 5-7%. This could be attributed 
to the lithotomy positioning of these patients during the procedure which causes an increase 
in the venous return to augment the cardiac output. In a study conducted by Miyabe M et al 
they compared the changes in the fall  of systolic BP after spinal in patients positioned in 
lithotomy position to that who were kept supine. He showed that there was a decreased fall in 
systolic BP in those who were in the lithotomy position37. None of these patients received 
vasopressors during the procedure. The ketamine group showed a 4% increase in diastolic 
BP at the end of the procedure probably due to a sympathomimetic effect.
Heart rate 
Bradycardia was noted in both the groups though studies show that ketamine causes 
an increase in heart rate. It could be due to loss of sympathetic drive and thereby causing a 
direct myocardial depressant effect.  Bhattacharya D et al in their study showed that 16% of 
patients in the study group had bradycardia though it was less when compared to 33% of 
patients in the control group30. Togal T et al had observed bradycardia in their patients27.
Side effects
Of all the patients only one (4.5%) belonging to the study group had delirium. 8 out of 
22 (36.36%) patients in the study group and one patient in the control group had vomiting. 
Kathirvel S et al had an increased incidence of side effects in their patients due to ketamine 
which included sedation, dizziness, nystagmus, `strange feelings' and postoperative nausea 
and vomiting. They had to terminate the study due to these adverse effects36, but Togal T et 
al did not have any significant difference in the incidence of adverse effects in his study 27.
The occurrence of pain
We also checked the mean difference between the pain scores, the time at which the 
patients complained of pain and the time at which they received the rescue analgesic. Mean 
(SD)  difference  of  pain  score  was  1.7273(0.99682) and  the  time  duration  was 
32.0227(24.54752) between the study and control groups.
CONCLUSION
            This study was conducted on patients diagnosed to have carcinoma cervix who 
underwent intracavitary HDR brachytherapy in two fractions. During the procedure 0.5mg/kg 
of preservative free ketamine added to 1.5 ml of hyperbaric bupivacaine was compared with 2 
ml of 0.5% hyperbaric bupivacaine injected intrathecally and this did not show any significant 
difference in terms of duration of analgesia, sensory and motor blockade irrespective of the 
number  of  fraction.  There  was  an  increased  incidence  of  side  effects  like  vomiting  and 
delirium in the study group.  Hence this study concludes that ketamine is not an effective 
spinal adjuvant drug for intracavitary brachytherapy.
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Intrathecal Ketamine with Bupivacaine study for Intracavitary HDR Brachytherapy 
SL No            :                                                                        Date  :   
 Name            :                                                                        Hospital No  :
 Age               :           Yrs              Height   :          cms         Weight :         kgs
Diagnosis      :                  
Premedication  :   Diazepam 5mg   and  Metaclopramide 10mg  1hr      prior surgery
Spinal Anesthesia                                                                                   
Technique as preferred by Anesthetist.
O2 through Hudsan mask 4lts/min . 
IV fluids NS as required.
Exclusion criteria  :   1]    ASA III / IV     2]  Wt < 35 kgs    3] Contraindication for spinal block
Inclusion criteria   :  All other than Exclusion criteria
Intra-operative  Events
 Side effects :  Illusions  /  Dreaming  /  Shivering / Pruritis  / Vomiting / Sedation / Nystagmus 
                                     Rescue drug given
 
Onset of sensory block is checked for pin prick at t10-12 level. Onset of motor block is tested by checking for 
absence of movement of foot.
Ist fraction
IInd fraction
mins 0 10 20 30 45 60 75 90 105 120
HR
BP
Spo2
Time
Time of spinal anesthesia
Onset of sensory block
Onset of motor block
Return of sensation
Return of foot movements
Time Drug
Amount of iv fluids given till u shift the pt out of OR :  _________ml
PAIN ASSESSMENT
VISUAL ANALOUGE SCALE
             0           1           2           3           4           5           6           7           8           9          10   
No pain                                                                     Worst Pain
Post-opearative
Time of first report of pain : am/pm               Pain score :    
                                                            Rescue  Drug  given
Side effects : Illusions  /  Dreaming  /  Shivering  /  Pruritis  /  Vomiting / Sedation / Nystagmus 
Rescue drugs :  
Vomiting         --    Inj Ondansetron  4mg  IV stat                                  
Hypotension   --    Inj Ephedrine 5mg IV stat, if SBP < 90mmHg  or  fall > 20% of 
baseline value. To be  repeated if necessary
             Pain                 --     Inj Tramadol 100 mg iv stat. 
Master chart : please look into the the xl sheet by name justinakmastersheet.  In the same 
cd. 
Time
Pain score
Drug 
